Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $72
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan maintains a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and raises the price target from $62 to $72.
August 10, 2023 | 7:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst maintains a Buy rating on ANI Pharmaceuticals and raises the price target from $62 to $72.
The news of Guggenheim maintaining a Buy rating and raising the price target for ANI Pharmaceuticals is likely to have a positive impact on the company's stock in the short term. This is because such news often leads to increased investor confidence, which can drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100